StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30285% above fair value
$144.46−3.30 (-2.23%)

Close on Nov 16, 2026Market cap $356.41BP/E 115.6Yield 2.27%

Merck total assets

Total assets on the balance sheet at the end of each period.

Merck's total assets was $129.80B at Jun 30, 2026. For fiscal 2025 it was $136.87B, up 16.9% from the year before. Over ten years it grew 3.0% a year on average. The highest annual figure on record is $136.87B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$136.87B+16.9%
FY2024Dec 31, 2024$117.11B+9.8%
FY2023Dec 31, 2023$106.68B-2.3%
FY2022Dec 31, 2022$109.16B+3.3%
FY2021Dec 31, 2021$105.69B+15.4%
FY2020Dec 31, 2020$91.59B+8.5%
FY2019Dec 31, 2019$84.40B+2.1%
FY2018Dec 31, 2018$82.64B-6.0%
FY2017Dec 31, 2017$87.87B-7.9%
FY2016Dec 31, 2016$95.38B-6.2%
FY2015Dec 31, 2015$101.68B+3.6%
FY2014Dec 31, 2014$98.17B-7.1%
FY2013Dec 31, 2013$105.65B-0.5%
FY2012Dec 31, 2012$106.13B+1.0%
FY2011Dec 31, 2011$105.13B-0.6%
FY2010Dec 31, 2010$105.78B-5.8%
FY2009Dec 31, 2009$112.31B+138.0%
FY2008Dec 31, 2008$47.20B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$129.80B+10.4%
Q1 FY2026Mar 31, 2026$128.69B+11.8%
Q4 FY2025Dec 31, 2025$136.87B+16.9%
Q3 FY2025Sep 30, 2025$129.55B+10.2%
Q2 FY2025Jun 30, 2025$117.52B+4.3%
Q1 FY2025Mar 31, 2025$115.12B+8.8%
Q4 FY2024Dec 31, 2024$117.11B+9.8%
Q3 FY2024Sep 30, 2024$117.53B+10.1%
Q2 FY2024Jun 30, 2024$112.63B+7.8%
Q1 FY2024Mar 31, 2024$105.85B-1.8%
Q4 FY2023Dec 31, 2023$106.68B-2.3%
Q3 FY2023Sep 30, 2023$106.73B-0.3%
Q2 FY2023Jun 30, 2023$104.47B-2.5%
Q1 FY2023Mar 31, 2023$107.80B+1.1%
Q4 FY2022Dec 31, 2022$109.16B+3.3%
Q3 FY2022Sep 30, 2022$107.08B+14.5%
Q2 FY2022Jun 30, 2022$107.10B+18.1%
Q1 FY2022Mar 31, 2022$106.67B+17.4%
Q4 FY2021Dec 31, 2021$105.69B+15.4%
Q3 FY2021Sep 30, 2021$93.49B+4.1%
Q2 FY2021Jun 30, 2021$90.69B+0.1%
Q1 FY2021Mar 31, 2021$90.85B+7.0%
Q4 FY2020Dec 31, 2020$91.59B+8.5%
Q3 FY2020Sep 30, 2020$89.80B+7.8%
Q2 FY2020Jun 30, 2020$90.62B+7.9%
Q1 FY2020Mar 31, 2020$84.91B+3.1%
Q4 FY2019Dec 31, 2019$84.40B+2.1%
Q3 FY2019Sep 30, 2019$83.33B-2.1%
Q2 FY2019Jun 30, 2019$83.97B-1.3%
Q1 FY2019Mar 31, 2019$82.35B-4.3%
Q4 FY2018Dec 31, 2018$82.64B-6.0%
Q3 FY2018Sep 30, 2018$85.13B-7.1%
Q2 FY2018Jun 30, 2018$85.04B-8.4%
Q1 FY2018Mar 31, 2018$86.04B-10.9%
Q4 FY2017Dec 31, 2017$87.87B-7.9%
Q3 FY2017Sep 30, 2017$91.68B-6.8%
Q2 FY2017Jun 30, 2017$92.80B–
Q1 FY2017Mar 31, 2017$96.56B–
Q4 FY2016Dec 31, 2016$95.38B–
Q3 FY2016Sep 30, 2016$98.34B–

More Merck figures

See a number that looks wrong?